Fig. 5From: Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosisRelative change in palpable spleen size reduction following ruxolitinib therapy at month 24 according to baseline BM characteristicsBack to article page